Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Biofrontera Inc. (BFRI)

1.6100 +0.1000 (+6.62%)
At close: September 4 at 4:00:01 PM EDT
1.6899 +0.0799 (+4.96%)
After hours: September 4 at 7:59:06 PM EDT
Chart Range Bar
Loading chart for BFRI
  • Previous Close 1.5100
  • Open 1.5200
  • Bid 1.1000 x 200
  • Ask 1.9900 x 200
  • Day's Range 1.5200 - 1.6300
  • 52 Week Range 0.5550 - 1.6300
  • Volume 630,605
  • Avg. Volume 438,207
  • Market Cap (intraday) 23.912M
  • Beta (5Y Monthly) 0.84
  • PE Ratio (TTM) --
  • EPS (TTM) -0.4300
  • Earnings Date Nov 11, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 6.00

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

www.biofrontera-us.com

84

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BFRI
182.46%
S&P 500 (^GSPC)
12.75%

1-Year Return

BFRI
91.90%
S&P 500 (^GSPC)
18.71%

3-Year Return

BFRI
81.13%
S&P 500 (^GSPC)
70.93%

5-Year Return

BFRI
98.03%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 10.08M
Earnings -4.75M
Profit Margin -47.12%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-5M
0
5M
10M
15M
-50.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

3.00
6.00 Average
1.6100 Current
9.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/19/2026
Analyst Benchmark
Rating Action Downgrade
Rating Speculative Buy
Price Action Maintains
Price Target 3 -> 3

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -13.79%

  • Return on Assets (ttm)

    -17.45%

  • Return on Equity (ttm)

    -988.35%

  • Revenue (ttm)

    46.17M

  • Net Income Avi to Common (ttm)

    -6.37M

  • Diluted EPS (ttm)

    -0.4300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.67M

  • Total Debt/Equity (mrq)

    125.99%

  • Levered Free Cash Flow (ttm)

    -7.6M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: